HHS Advances Lyme Disease Diagnostics and Patient Care with LymeX Renewal
HHS renews LymeX Innovation Accelerator to boost AI-driven diagnostics and expands Medicare support for Lyme disease patients, advancing national care strategies.
HHS renews LymeX Innovation Accelerator to boost AI-driven diagnostics and expands Medicare support for Lyme disease patients, advancing national care strategies.
CMS and FDA introduce ACCESS and TEMPO programs to foster value-based reimbursement and regulatory flexibility for digital health technologies targeting chronic conditions starting 2026.
Analysis of ongoing robocall campaigns marketing insurance and financial services, highlighting compliance and regulatory challenges in the U.S. insurance industry.
Internal Humana data revealed higher hospitalization rates in their Medicare Advantage clinics than publicly reported, raising questions on integrated care outcomes and investor transparency.
Examining the critical staffing shortages and proposed Medicare reimbursement cuts impacting home health care providers in New Hampshire and across the U.S., affecting service availability and patient care continuity.
Humana's fair value rises slightly on stronger revenue growth assumptions despite mixed analyst ratings amid Medicare Advantage regulatory challenges and sector cyclicality.
The 2024 State of Oral Health Equity in America survey finds 27% of U.S. adults lack dental insurance, highlighting the need to expand Medicare, Medicaid, and ACA dental benefits to improve systemic health outcomes.
U.S. Senators propose legislation to halt CMS AI-powered Medicare prior authorization pilot in six states including Washington due to care delay concerns.
Explore key Medicare enrollment periods for 2026 including the Annual Enrollment Period, Open Enrollment for Advantage Plans, Special Election Periods for new and transitioning beneficiaries, and Medicare Supplement enrollment guidelines.
CMS 2027 Proposed Rule aims to modernize Medicare Advantage and Part D programs with updates to quality metrics, risk adjustment models, and beneficiary protections. Key changes include Star Ratings revisions, incorporation of Inflation Reduction Act drug pricing provisions, and requests for stakeholder feedback on quality bonus payments and care coordination.